Could fewer treatments keep advanced prostate cancer in check?

This study is testing a new approach for giving a targeted radiation drug to men with advanced prostate cancer that has stopped responding to hormone therapy. It will compare the standard schedule of six doses given every six weeks to a new approach where, after two successful doses, further treatment is delayed until there are signs the cancer is becoming active again. The main goal is to see if this flexible timing can maintain or improve patients' quality of life without reducing how long they live.